Prolymphocytic leukemia

被引：8

作者：

Absi A. ^{[1
]}

Hsi E. ^{[1
]}

Kalaycio M. ^{[1
]}

机构：

[1] Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195

来源：

Current Treatment Options in Oncology | 2005年 / 6卷 / 3期

关键词：

Chronic Lymphocytic Leukemia; Fludarabine; Mantle Cell Lymphoma; Alemtuzumab; Ataxia Telangiectasia Mutate;

D O I：

10.1007/s11864-005-0003-4

中图分类号：

学科分类号：

摘要：

Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features. T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy. With the use of the purine analogue pentostatin more than half of patients will have a major response and a minority will have a complete remission, usually lasting months. With the introduction of alemtuzumab, most patients who progressed despite treatment with pentostatin had a major response with a complete remission rate higher than that obtained with pentostatin when used as a first line. Unfortunately, progression still follows shortly. We recommend alemtuzumab as initial therapy and offer stem cell transplant (SCT) to selected young, healthy patients who respond. Although B-cell prolymphocytic leukemia is also a progressive disease, some patients can achieve a prolonged progression-free-survival with fludarabine. Patients presenting with massive splenomegaly may be effectively palliated with splenic irradiation or splenectomy. Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder. Copyright © 2005 by Current Science Inc.

引用

页码：197 / 208

页数：11

共 54 条

[1]

Matutes E., Brito-Babapulle V., Swansbury J., Et al., Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia, Blood, 78, pp. 3269-3274, (1991)

[2]

Pawson R., Schulz T.F., Matutes E., Et al., The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia, Leukemia, 11, pp. 1305-1311, (1997)

[3]

Brito-Babapulle V., Maljaie S.H., Matutes E., Et al., Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: A cytogenetic analysis with in situ hybridization, Br. J. of Haematol., 96, pp. 724-732, (1997)

[4]

Jaffe E.S., Harris N.L., Stein H., Vardiman J.W., Pathology and Genetics of Tumours of Haematopoietic and Lympkoid Tissues, (2001)

[5]

Ginaldi L., De Martinis M., Matutes E., Et al., Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H, Leuk. Res., 22, pp. 185-191, (1998)

[6]

Virgilio L., Lazzeri C., Bichi R., Et al., Deregulated expression of TCL1 causes T-cell leukemia in mice, Proc. Natl. Acad. Sci., 95, pp. 3885-3889, (1998)

[7]

Pekarsky Y., Hallas C., Isobe M., Et al., Abnormalities at 14q32.1 in T-cell malignancies involve two oncogenes, Proc. Natl. Acad. Sci., 96, pp. 2949-2951, (1999)

[8]

Stilgenbauer S., Schaffner C., Litterst A., Et al., Biallelic mutations in the ATM gene in T-prolymphocytic leukemia, Nat. Med., 3, pp. 1155-1159, (1997)

[9]

Shvidel L., Shtalrid M., Bassous L., Et al., B-cell prolymphocytic leukemia: A survey of 35 patients emphasizing heterogeneity, prognostic factors, and evidence for a group with an indolent course, Leuk. Lymphoma, 33, pp. 169-179, (1999)

[10]

Hercher C., Robain M., Davi F., Et al., A multicentric study of 41 cases of B-prolymphocytic leukemia: Two evolutive forms, Leuk. Lymphoma, 42, 5, pp. 981-987, (2001)

← 1 2 3 4 5 6 →